Tao Qin. "A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps2692